Leerink Partnrs Has Weak Outlook for Danaher FY2024 Earnings

Danaher Co. (NYSE:DHR) – Stock analysts at Leerink Partnrs lowered their FY2024 earnings per share estimates for shares of Danaher in a report issued on Tuesday, October 22nd. Leerink Partnrs analyst P. Souda now expects that the conglomerate will earn $7.49 per share for the year, down from their previous forecast of $7.60. The consensus estimate for Danaher’s current full-year earnings is $7.59 per share. Leerink Partnrs also issued estimates for Danaher’s Q1 2025 earnings at $2.06 EPS, Q2 2025 earnings at $1.90 EPS, Q3 2025 earnings at $1.87 EPS, Q4 2025 earnings at $2.47 EPS, FY2025 earnings at $8.30 EPS and FY2026 earnings at $9.31 EPS.

A number of other research firms have also weighed in on DHR. Robert W. Baird reduced their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday. Stephens reiterated an “overweight” rating and set a $315.00 price objective on shares of Danaher in a research note on Wednesday. Royal Bank of Canada dropped their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday. The Goldman Sachs Group upped their price objective on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Finally, Leerink Partners lifted their target price on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $287.28.

Danaher Stock Performance

DHR opened at $245.39 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. Danaher has a 12-month low of $182.09 and a 12-month high of $281.70. The firm has a 50 day moving average of $269.52 and a two-hundred day moving average of $260.42. The firm has a market capitalization of $181.76 billion, a PE ratio of 41.59, a P/E/G ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the company earned $2.02 earnings per share. The company’s revenue was up 3.1% on a year-over-year basis.

Institutional Investors Weigh In On Danaher

Several hedge funds and other institutional investors have recently bought and sold shares of DHR. Good Life Advisors LLC acquired a new stake in shares of Danaher during the 3rd quarter worth approximately $217,000. Oak Thistle LLC acquired a new position in shares of Danaher in the 2nd quarter valued at $363,000. Norden Group LLC purchased a new position in shares of Danaher during the 1st quarter worth $4,151,000. Duality Advisers LP acquired a new stake in shares of Danaher during the 1st quarter worth about $5,573,000. Finally, Investment Research & Advisory Group Inc. acquired a new position in Danaher in the first quarter valued at about $1,186,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,059 shares of company stock worth $8,400,897. 11.10% of the stock is owned by corporate insiders.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio is presently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.